← Back to Search

Vaccine

HPV Vaccine Reminder Intervention for Healthy Young Men

N/A
Waitlist Available
Led By Paul Reiter, PhD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Cisgender male
Ages 18-25
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline up to 9 months
Awards & highlights

Summary

This trial will study how well a population-targeted, individually-tailored mHealth intervention that includes vaccine reminders works in increasing HPV vaccine initiation and completion among unvaccinated young sexual minority individuals.

Who is the study for?
This trial is for young cisgender males aged 18-25 in the US who identify as gay, bisexual, or queer, have not had any HPV vaccine doses, and can give informed consent. Participants must be able to read English and should not have taken part in the pilot study.Check my eligibility
What is being tested?
The trial tests the 'Outsmart HPV' intervention designed to increase HPV vaccine uptake among sexual minority males. It includes personalized mobile health components like reminders to initiate and complete the vaccination process.See study design
What are the potential side effects?
Since this trial focuses on an informational intervention rather than a medical treatment, traditional side effects are not applicable. However, participants may experience inconvenience or privacy concerns related to receiving text messages.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a cisgender male.
Select...
I am between 18 and 25 years old.
Select...
I have never received an HPV vaccine.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline up to 9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to 9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in Theoretical Constructs
Counts of Human Papillomavirus (HPV) Vaccine Initiation by Participant Characteristics
Human Papillomavirus (HPV) Vaccine Initiation and Completion

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Group C (Outsmart HPV, interactive vaccine reminders)Experimental Treatment3 Interventions
Participants receive Outsmart HPV with interactive vaccine reminders (i.e. reminders that allow participants to respond).
Group II: Group B (Outsmart HPV, unidirectional vaccine reminders)Experimental Treatment3 Interventions
Participants receive Outsmart HPV with unidirectional vaccine reminders (i.e. reminders that do not give participants the option to respond).
Group III: Group A (standard HPV information)Active Control2 Interventions
Participants receive standard information about HPV and HPV vaccine via a mobile-friendly website.

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
325 Previous Clinical Trials
289,377 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,748 Previous Clinical Trials
40,958,174 Total Patients Enrolled
Paul Reiter, PhDPrincipal Investigator - Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
2 Previous Clinical Trials
253 Total Patients Enrolled

Media Library

Outsmart HPV intervention (Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT04032106 — N/A
Healthy Subjects Research Study Groups: Group C (Outsmart HPV, interactive vaccine reminders), Group A (standard HPV information), Group B (Outsmart HPV, unidirectional vaccine reminders)
Healthy Subjects Clinical Trial 2023: Outsmart HPV intervention Highlights & Side Effects. Trial Name: NCT04032106 — N/A
Outsmart HPV intervention (Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04032106 — N/A
~213 spots leftby Jul 2025